180 Life Sciences Adalimumab Study Publishes Positive IIb Dupuytren’s Disease Data
Company Has Started Initial Consultations With US And UK Regulators
Adalimumab could find itself with a tenth official indication, after 180 Life Sciences found that it was able to effectively treat nodule hardness and size in Dupuytren’s disease during a phase IIb study.
You may also be interested in...
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.